

L5 ANSWER 2 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:695729 CAPLUS

DOCUMENT NUMBER: 137:231345

TITLE: Immunogenic compositions comprising MHC epitopes of PSMA, VEGFR2 and fibronectin for use as anti-neovasculature and cancer therapy

INVENTOR(S): Simard, John J. L.; Diamond, David C.

PATENT ASSIGNEE(S): CTL Immunotherapies Corp., USA; Mannkind Corp.

SOURCE: PCT Int. Appl., 73 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069907	A2	20020912	WO 2002-US7204	20020307 <--
WO 2002069907	A3	20030213		
WO 2002069907	A8	20040212		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002247304	A1	20020919	AU 2002-247304	20020307 <--
US 2003046714	A1	20030306	US 2002-94699	20020307
EP 1372736	A2	20040102	EP 2002-715085	20020307
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2005505242	T	20050224	JP 2002-569085	20020307
EP 1595548	A2	20051116	EP 2005-14175	20020307
EP 1595548	A3	20060222		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR			
CN 1703247	A	20051130	CN 2002-806006	20020307
US 2005260234	A1	20051124	US 2005-73347	20050630
PRIORITY APPLN. INFO.:			US 2001-274063P	P 20010307
			EP 2002-715085	A3 20020307
			US 2002-94699	A1 20020307
			WO 2002-US7204	W 20020307
AB	Disclosed herein are immunogenic compns., methods of designing immunogenic compns., methods of treatment using immunogenic compns., methods of evaluating cell-mediated immunity resulting from immunogenic compns., research models, and methods of making research models, all of which relate to targeting tumor vasculature. The antitumor compns. comprise cytotoxic T lymphocyte epitopes derived from prostate specific membrane antigen, vascular epithelial growth factor or ED-B domain of fibronectin.			
IT	457998-20-8			
RL:	BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(amino acid sequence; immunogenic compns. comprising MHC epitopes of PSMA, VEGFR2 and fibronectin for use as anti-neovasculature and cancer therapy)			
RN	457998-20-8 CAPLUS			
CN	Antigen PSMA (prostate-specific membrane antigen) (human) (9CI) (CA INDEX NAME)			

SEQ 1 MWNLLHETDS AVATARRPRW LCAGALVLAG GFFLLGFLFG WFIKSSNEAT
 51 NITPKHNMKA FLDELKAENI KKFLYNFTQI PHLAGTEQNF QLAKQIQSQW
 101 KEFGLDSVEL AHYDVLLSYP NKTHPNYISI INEDGNEIFN TSLFEP PPPG
 151 YENVSDIVPP FSAFSPQGMP EGDLYVYVNYA RTEDFFKLER DMKINCSGKI
 201 VIARYGKVFR GNKVNAQLA GAKGVILYSD PADYFAPGVK SYPDGWNLP
 251 GGVQRGNILN LNGAGDPLTP GYPANEYAYR RGIAEAVGLP SIPVHPIGYY
 301 DAQKLEKMG GSAPPDSSWR GSLKVPYNVG PGFTGNFSTQ KVKMHIHSTN
 351 EVTRIYNVIG TLRGAVEPDR YVILGGHRDS WVFGGIDPQS GAAVVHEIVR
 401 SFGTLKKEGW RPRRTILFAS WDAEEFGLLG STEWAEENSRLQERGVAYI
 451 NADSSIEGNY TLRVDCTPLM YSLVHNLTKL KSPDEGFEG KSLYESWTKK
 501 SPSPEFSGMP RISKLGSGND FEVFFQRLGI ASGRARYTKN WETNKFSGYP
 551 LYHSVYETYE LVEKFYDPMF KYHLTVAQVR GGMVFELANS IVLPFDCRDY
 601 AVVLRKYADK IYSISMKHPQ EMKTYSVSFD SLFSAVKNFT EIASKFSERL
 651 QDFDKSNPIV LRMMNDQLMF LERAFIDPLG LPDRPFYRHV IYAPSSHNKY
 701 AGESFPGIYD ALFDIESKVD PSKAWGEVKR QIYVAAFTVQ AAAETLSEVA

L5 ANSWER 4 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:693506 CAPLUS

DOCUMENT NUMBER: 135:268240

TITLE: Secreted and transmembrane polypeptides and human nucleic acids encoding them that are overexpressed in cancerous tissues

INVENTOR(S): Baker, Kevin P.; Chen, Jian; Desnoyers, Luc; Goddard, Audrey; Godowski, Paul J.; Gurney, Austin L.; Pan, James; Smith, Victoria; Watanabe, Colin K.; Wood, William I.; Zhang, Zemin

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 774 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 150

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068848	A2	20010920	WO 2001-US6520	20010228 <--
WO 2001068848	A3	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AT 310810	T	20051215	AT 2001-127791	19980916
ES 2253320	T3	20060601	ES 2001-127791	19980916
NZ 528704	A	20050225	NZ 1999-528704	19990308
CA 2450824	A1	20000420	CA 1999-2450824	19991005 <--
EP 1466977	A1	20041013	EP 2004-7618	19991202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
NZ 523206	A	20041224	NZ 2000-523206	20000211
NZ 523207	A	20041224	NZ 2000-523207	20000211
NZ 523208	A	20041224	NZ 2000-523208	20000211
NZ 523209	A	20041224	NZ 2000-523209	20000211
WO 2000056889	A2	20000928	WO 2000-US5601	20000301 <--
WO 2000056889	A3	20010426		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2000053758 A2 20000914 WO 2000-US5841 20000302 <--
 WO 2000053758 A3 20010208

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2001005972 A1 20010125 WO 2000-US6884 20000315 <--
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

WO 2000073454 A1 20001207 WO 2000-US8439 20000330 <--
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2380355 A1 20010308 CA 2000-2380355 20000824 <--
 CA 2481685 A1 20010308 CA 2000-2481685 20000824 <--
 CA 2481691 A1 20010308 CA 2000-2481691 20000824 <--
 CA 2481731 A1 20010308 CA 2000-2481731 20000824 <--
 CA 2481756 A1 20010308 CA 2000-2481756 20000824 <--
 CA 2481788 A1 20010308 CA 2000-2481788 20000824 <--
 EP 1259614 A2 20021127 EP 2001-945919 20010228 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2003199034 A1 20031023 US 2001-156846 20010528
 EP 1286749 A1 20030305 EP 2001-939834 20010601
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

EP 1657251 A2 20060517 EP 2005-24036 20010601
 EP 1657251 A3 20060524
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, AL, TR

EP 1659177 A2 20060524 EP 2005-24032 20010601
 EP 1659177 A3 20060531
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, AL, TR

EP 1666597 A2 20060607 EP 2005-24025 20010601
 EP 1666597 A3 20061102
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, AL, TR

EP 1666596 A1 20060607 EP 2005-24027 20010601
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, AL, TR

EP 1666491	A1	20060607	EP 2005-24030	20010601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, AL, TR				
EP 1666492	A1	20060607	EP 2005-24031	20010601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, AL, TR				
EP 1666493	A1	20060607	EP 2005-24033	20010601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, AL, TR				
EP 1666497	A2	20060607	EP 2005-24034	20010601
EP 1666497	A3	20060621		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, AL, TR				
EP 1666594	A2	20060607	EP 2005-24035	20010601
EP 1666594	A3	20060621		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, AL, TR				
EP 1683864	A2	20060726	EP 2005-24023	20010601
EP 1683864	A3	20060816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
EP 1686174	A1	20060802	EP 2005-24028	20010601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, AL, TR				
EP 1700867	A2	20060913	EP 2005-24037	20010601
EP 1700867	A3	20060920		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, AL, TR				
EP 1702928	A2	20060920	EP 2005-24038	20010601
EP 1702928	A3	20060927		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, AL, TR				
WO 2002016429	A2	20020228	WO 2001-US20118	20010622 <--
WO 2002016429	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 200170118	A	20020304	AU 2001-70118	20010622 <--
AU 200173150	A	20020130	AU 2001-73150	20010702 <--
AU 200171973	A	20020205	AU 2001-71973	20010709 <--
AU 758921	B2	20030403	AU 2001-57764	20010801
AU 759004	B2	20030403	AU 2001-57765	20010801
WO 2002016581	A2	20020228	WO 2001-US25464	20010814 <--
WO 2002016581	A3	20030116		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 200184906	A	20020304	AU 2001-84906	20010814 <--
CA 2420193	A1	20020228	CA 2001-2420193	20010823 <--
WO 2002016602	A2	20020228	WO 2001-US26626	20010823 <--
WO 2002016602	A3	20030206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,	
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,	
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,	
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,	
	US, UZ, VN, YU, ZA, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,	
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,	
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
AU 200186785	A	20020304 AU 2001-86785 20010823 <--
US 2002161199	A1	20021031 US 2001-938418 20010823 <--
JP 2004520810	T	20040715 JP 2002-522275 20010823
US 2002102647	A1	20020801 US 2001-944449 20010830 <--
US 2002110859	A1	20020815 US 2001-944457 20010830 <--
US 6734288	B2	20040511
US 2002132981	A1	20020919 US 2001-944396 20010830 <--
US 2002142958	A1	20021003 US 2001-943762 20010830 <--
US 2002142419	A1	20021003 US 2001-944432 20010830 <--
US 2002156004	A1	20021024 US 2001-944413 20010830 <--
US 2002165143	A1	20021107 US 2001-944403 20010830 <--
US 2002115145	A1	20020822 US 2001-944862 20010831 <--
US 2002127643	A1	20020912 US 2001-945587 20010831 <--
US 6936254	B2	20050830
US 2002132768	A1	20020919 US 2001-945015 20010831 <--
US 2002142959	A1	20021003 US 2001-944654 20010831 <--
US 2002173463	A1	20021121 US 2001-944944 20010831 <--
US 6929947	B2	20050816
US 2002198147	A1	20021226 US 2001-944907 20010831
US 2003073129	A1	20030417 US 2001-946374 20010904
AU 200216610	A	20020402 AU 2002-16610 20010919 <--
US 2002137909	A1	20020926 US 2001-964994 20010926 <--
US 6740520	B2	20040525
US 2003207803	A1	20031106 US 2001-143026 20011019
US 2003199021	A1	20031023 US 2001-13924 20011025
WO 2002070706	A2	20020912 WO 2001-US48060 20011207 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,	
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,	
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,	
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,	
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,	
	US, UZ, VN, YU, ZA, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,	
	CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,	
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
EP 1397383	A2	20040317 EP 2001-990229 20011213
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,	
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
US 2002090681	A1	20020711 US 2001-36342 20011226 <--
AU 772759	B2	20040506 AU 2002-14767 20020201
AU 772723	B2	20040506 AU 2002-14769 20020201
AU 772734	B2	20040506 AU 2002-14771 20020201
AU 778585	B2	20041209 AU 2002-14753 20020201
CA 2449602	A1	20021219 CA 2002-2449602 20020403 <--
WO 2002101069	A2	20021219 WO 2002-US10513 20020403 <--
WO 2002101069	A3	20030904
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,	
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,	
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,	
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,	
	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,	
	UA, UG, UZ, VN, YU, ZA, ZW	
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,	
	KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,	
	GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,	
	GN, GQ, GW, ML, MR, NE, SN, TD, TG	

EP 1402260	A2	20040331	EP 2002-731246	20020403
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005500030	T	20050106	JP 2003-503819	20020403
US 2003039648	A1	20030227	US 2002-125166	20020417
US 2003087349	A1	20030508	US 2002-125928	20020419
US 2003087355	A1	20030508	US 2002-127828	20020422
US 2003027992	A1	20030206	US 2002-63524	20020502
US 2003027993	A1	20030206	US 2002-63537	20020502
US 2003027212	A1	20030206	US 2002-63544	20020502
US 2003027986	A1	20030206	US 2002-63549	20020502
US 2003045684	A1	20030306	US 2002-63553	20020502
US 2003055222	A1	20030320	US 2002-63534	20020502
US 2003013855	A1	20030116	US 2002-63616	20020503
US 2003050462	A1	20030313	US 2002-63598	20020503
US 2003092110	A1	20030515	US 2002-137864	20020503
US 2003092111	A1	20030515	US 2002-137869	20020503
US 2003138885	A1	20030724	US 2002-140018	20020506
US 2003143674	A1	20030731	US 2002-140274	20020506
US 2003134354	A1	20030717	US 2002-140807	20020507
US 2003134355	A1	20030717	US 2002-140924	20020507
US 2003134356	A1	20030717	US 2002-140926	20020507
US 2003138889	A1	20030724	US 2002-140922	20020507
US 2003148425	A1	20030807	US 2002-140861	20020507
US 2003207352	A1	20031106	US 2002-140806	20020507
US 2003207353	A1	20031106	US 2002-140810	20020507
US 2003207354	A1	20031106	US 2002-140863	20020507
US 2003207355	A1	20031106	US 2002-140923	20020507
US 2004009548	A1	20040115	US 2002-140927	20020507
US 2003134357	A1	20030717	US 2002-141698	20020508
US 2003148427	A1	20030807	US 2002-141697	20020508
US 2003148428	A1	20030807	US 2002-141700	20020508
US 2003148429	A1	20030807	US 2002-141705	20020508
US 2003148430	A1	20030807	US 2002-141753	20020508
US 2003148431	A1	20030807	US 2002-141758	20020508
US 2003148432	A1	20030807	US 2002-141761	20020508
US 2003207356	A1	20031106	US 2002-141699	20020508
US 2003207358	A1	20031106	US 2002-141706	20020508
US 2003207360	A1	20031106	US 2002-141757	20020508
US 2003207362	A1	20031106	US 2002-141762	20020508
US 2006008901	A1	20060112	US 2002-63703	20020508
US 2003134360	A1	20030717	US 2002-142421	20020509
US 2003134361	A1	20030717	US 2002-142432	20020509
US 2003148434	A1	20030807	US 2002-142420	20020509
US 2003148435	A1	20030807	US 2002-142422	20020509
US 2003148436	A1	20030807	US 2002-142427	20020509
US 2003157606	A1	20030821	US 2002-142888	20020509
US 2003157607	A1	20030821	US 2002-143034	20020509
US 2003157608	A1	20030821	US 2002-143116	20020509
US 2003166071	A1	20030904	US 2002-143035	20020509
US 2003180864	A1	20030925	US 2002-142762	20020509
US 2003194765	A1	20031016	US 2002-142889	20020509
US 2003207363	A1	20031106	US 2002-142428	20020509
US 2003207366	A1	20031106	US 2002-143027	20020509
US 2003207367	A1	20031106	US 2002-143115	20020509
US 2004038335	A1	20040226	US 2002-143118	20020509
US 2004048333	A1	20040311	US 2002-142426	20020509
US 2003134362	A1	20030717	US 2002-142767	20020510
US 2003180866	A1	20030925	US 2002-142766	20020510
US 2003134364	A1	20030717	US 2002-144994	20020513
US 2003157613	A1	20030821	US 2002-145090	20020513
US 2003207368	A1	20031106	US 2002-144956	20020513
US 2004038336	A1	20040226	US 2002-144993	20020513
US 2003134368	A1	20030717	US 2002-145823	20020514

US 2003148438	A1	20030807	US 2002-145821	20020514
US 2003166077	A1	20030904	US 2002-145827	20020514
US 2003170788	A1	20030911	US 2002-145634	20020514
US 2003180868	A1	20030925	US 2002-145625	20020514
US 2003180870	A1	20030925	US 2002-145960	20020514
US 2003180871	A1	20030925	US 2002-145962	20020514
US 2003166084	A1	20030904	US 2002-146793	20020515
US 2003134380	A1	20030717	US 2002-147509	20020516
US 2004214269	A1	20041028	US 2002-147518	20020516
US 2003134381	A1	20030717	US 2002-147510	20020517
US 2003180875	A1	20030925	US 2002-147505	20020517
US 2003148439	A1	20030807	US 2002-152531	20020520
US 2003157630	A1	20030821	US 2002-152401	20020520
US 2003199026	A1	20031023	US 2002-152393	20020520
US 2003199027	A1	20031023	US 2002-152396	20020520
US 2003211571	A1	20031113	US 2002-152405	20020520
US 2003166094	A1	20030904	US 2002-152379	20020521
US 2003166095	A1	20030904	US 2002-152394	20020521
US 2003175867	A1	20030918	US 2002-152382	20020521
US 2003175868	A1	20030918	US 2002-152383	20020521
US 2003175869	A1	20030918	US 2002-152384	20020521
US 2003175870	A1	20030918	US 2002-152387	20020521
US 2003175871	A1	20030918	US 2002-152389	20020521
US 2003175872	A1	20030918	US 2002-152390	20020521
US 2003175873	A1	20030918	US 2002-152392	20020521
US 2003175874	A1	20030918	US 2002-152403	20020521
US 2003194768	A1	20031016	US 2002-152371	20020521
US 2003194772	A1	20031016	US 2002-152386	20020521
US 2003194774	A1	20031016	US 2002-152399	20020521
US 2003199025	A1	20031023	US 2002-152385	20020521
US 2003207381	A1	20031106	US 2002-152376	20020521
US 2003207382	A1	20031106	US 2002-152381	20020521
US 2004126839	A1	20040701	US 2002-152372	20020521
US 2003175875	A1	20030918	US 2002-153756	20020522
US 2003199028	A1	20031023	US 2002-153552	20020522
US 2003199029	A1	20031023	US 2002-153840	20020522
US 2003207384	A1	20031106	US 2002-153585	20020522
US 2003166098	A1	20030904	US 2002-156847	20020528
US 2003194775	A1	20031016	US 2002-156848	20020528
US 2003199030	A1	20031023	US 2002-156841	20020528
US 2003199032	A1	20031023	US 2002-156844	20020528
US 2003166100	A1	20030904	US 2002-157778	20020529
US 2003170790	A1	20030911	US 2002-157781	20020529
US 2003175878	A1	20030918	US 2002-157784	20020529
US 2003175879	A1	20030918	US 2002-157797	20020529
US 2003175880	A1	20030918	US 2002-158491	20020529
US 2005074837	A1	20050407	US 2002-158788	20020530
US 2003104538	A1	20030605	US 2002-173701	20020617
US 2003166104	A1	20030904	US 2002-173689	20020617
US 2003166105	A1	20030904	US 2002-173690	20020617
US 2003166106	A1	20030904	US 2002-173691	20020617
US 2003166188	A1	20030904	US 2002-173692	20020617
US 2003166107	A1	20030904	US 2002-173694	20020617
US 2003166108	A1	20030904	US 2002-173698	20020617
US 2003166109	A1	20030904	US 2002-173699	20020617
US 2003166110	A1	20030904	US 2002-173707	20020617
US 2003170793	A1	20030911	US 2002-173702	20020617
US 2003170794	A1	20030911	US 2002-173703	20020617
US 2003170795	A1	20030911	US 2002-173704	20020617
US 2003017540	A1	20030123	US 2002-174581	20020618
US 7153939	B2	20061226		
US 2003032104	A1	20030213	US 2002-174576	20020618
US 7125962	B2	20061024		
US 2003166111	A1	20030904	US 2002-174569	20020618

US 2003166112	A1	20030904	US 2002-174583	20020618
US 2003166113	A1	20030904	US 2002-174587	20020618
US 2003166114	A1	20030904	US 2002-174589	20020618
US 2003166115	A1	20030904	US 2002-174591	20020618
US 2003170796	A1	20030911	US 2002-174574	20020618
US 2003211572	A1	20031113	US 2002-174570	20020618
US 2003166117	A1	20030904	US 2002-175736	20020619
US 2003166118	A1	20030904	US 2002-175742	20020619
US 2003166119	A1	20030904	US 2002-175744	20020619
US 2003166120	A1	20030904	US 2002-175745	20020619
US 2003166121	A1	20030904	US 2002-175748	20020619
US 2003166122	A1	20030904	US 2002-175751	20020619
US 2003166123	A1	20030904	US 2002-175754	20020619
US 2005196832	A1	20050908	US 2002-175749	20020619
US 2003166126	A1	20030904	US 2002-176754	20020620
US 2003166128	A1	20030904	US 2002-176759	20020620
US 2003166129	A1	20030904	US 2002-176920	20020620
US 2003170798	A1	20030911	US 2002-176490	20020620
US 2003170800	A1	20030911	US 2002-176981	20020620
US 2003170802	A1	20030911	US 2002-176988	20020620
US 2003170803	A1	20030911	US 2002-176989	20020620
US 2003166124	A1	20030904	US 2002-176480	20020621
US 2003166125	A1	20030904	US 2002-176489	20020621
US 2003166127	A1	20030904	US 2002-176755	20020621
US 2003166130	A1	20030904	US 2002-176922	20020621
US 2003166131	A1	20030904	US 2002-176924	20020621
US 2003170797	A1	20030911	US 2002-176486	20020621
US 2003170799	A1	20030911	US 2002-176752	20020621
US 2003170801	A1	20030911	US 2002-176983	20020621
US 2003104539	A1	20030605	US 2002-179511	20020624
US 2003104540	A1	20030605	US 2002-179518	20020624
US 2003166133	A1	20030904	US 2002-179508	20020624
US 2003166134	A1	20030904	US 2002-179512	20020624
US 2003166135	A1	20030904	US 2002-179515	20020624
US 2003170805	A1	20030911	US 2002-179517	20020624
US 2003170806	A1	20030911	US 2002-179521	20020624
US 2003207392	A1	20031106	US 2002-179509	20020624
US 2003215909	A1	20031120	US 2002-179523	20020624
US 2003032119	A1	20030213	US 2002-180544	20020625
US 2003036121	A1	20030220	US 2002-180542	20020625
US 2005202526	A1	20050915	US 2002-180554	20020625
US 2003036124	A1	20030220	US 2002-180998	20020626
US 7087421	B2	20060808		
US 2003104541	A1	20030605	US 2002-183018	20020626
US 2003124661	A1	20030703	US 2002-183009	20020626
US 2003211574	A1	20031113	US 2002-183005	20020626
US 2005163766	A1	20050728	US 2002-183001	20020626
US 7084255	B2	20060801		
US 2003119105	A1	20030626	US 2002-184613	20020627
US 2003157635	A1	20030821	US 2002-184642	20020627
US 2003104542	A1	20030605	US 2002-184624	20020628
US 2003104543	A1	20030605	US 2002-184657	20020628
US 2003068687	A1	20030410	US 2002-187748	20020701
US 2003073175	A1	20030417	US 2002-187888	20020701
US 2003087376	A1	20030508	US 2002-187592	20020701
US 2003032138	A1	20030213	US 2002-187885	20020702
US 2003068695	A1	20030410	US 2002-192012	20020709
US 2003068696	A1	20030410	US 2002-192014	20020709
US 2003104544	A1	20030605	US 2002-192007	20020709
US 2003207395	A1	20031106	US 2002-192011	20020709
US 2003049743	A1	20030313	US 2002-194394	20020711
US 2003049745	A1	20030313	US 2002-194485	20020711
US 2003064446	A1	20030403	US 2002-194460	20020711
US 2003153037	A1	20030814	US 2002-194457	20020711

US 2003059879	A1	20030327	US 2002-194456	20020712
US 2003064448	A1	20030403	US 2002-194484	20020712
US 2006074226	A1	20060406	US 2002-194487	20020712
US 2003049746	A1	20030313	US 2002-195885	20020715
US 2003050459	A1	20030313	US 2002-195890	20020715
US 2003049747	A1	20030313	US 2002-195899	20020715
US 2003064449	A1	20030403	US 2002-195884	20020715
US 2003063112	A1	20030403	US 2002-195896	20020715
US 2003068705	A1	20030410	US 2002-195886	20020715
US 2003068706	A1	20030410	US 2002-195891	20020715
US 2003073178	A1	20030417	US 2002-195895	20020715
US 2003071834	A1	20030417	US 2002-195898	20020715
US 2003206187	A1	20031106	US 2002-195887	20020715
US 2003207397	A1	20031106	US 2002-195900	20020715
US 2006073544	A1	20060406	US 2002-195883	20020715
US 2006073545	A1	20060406	US 2002-195888	20020715
US 2006074227	A1	20060406	US 2002-195889	20020715
US 2003049748	A1	20030313	US 2002-196748	20020716
US 2003049749	A1	20030313	US 2002-196750	20020716
US 2003054461	A1	20030320	US 2002-196751	20020716
US 2003059880	A1	20030327	US 2002-196758	20020716
US 2003064451	A1	20030403	US 2002-196755	20020716
US 2003065159	A1	20030403	US 2002-196757	20020716
US 2003068707	A1	20030410	US 2002-196746	20020716
US 2003068709	A1	20030410	US 2002-196753	20020716
US 2003067478	A1	20030410	US 2002-196754	20020716
US 2003068710	A1	20030410	US 2002-196761	20020716
US 2003162250	A1	20030828	US 2002-196747	20020716
US 2006094864	A1	20060504	US 2002-196749	20020716
US 2003040079	A1	20030227	US 2002-197695	20020717
US 2003104547	A1	20030605	US 2002-197701	20020717
US 2003104548	A1	20030605	US 2002-197706	20020717
US 2003207398	A1	20031106	US 2002-198759	20020718
US 2003215910	A1	20031120	US 2002-199463	20020718
US 2003049767	A1	20030313	US 2002-201534	20020722
US 2003096357	A1	20030522	US 2002-201325	20020722
US 2003068739	A1	20030410	US 2002-201769	20020723
US 7087737	B2	20060808		
US 2003180881	A1	20030925	US 2002-202475	20020723
US 2003049777	A1	20030313	US 2002-202939	20020724
US 2003045700	A1	20030306	US 2002-205908	20020725
US 2003049783	A1	20030313	US 2002-205909	20020725
US 2003054482	A1	20030320	US 2002-205902	20020725
US 2003059885	A1	20030327	US 2002-205893	20020725
US 2003049782	A1	20030313	US 2002-205900	20020726
US 2003064462	A1	20030403	US 2002-206919	20020726
US 2003064463	A1	20030403	US 2002-206922	20020726
US 2003068754	A1	20030410	US 2002-206910	20020726
US 2003068756	A1	20030410	US 2002-206912	20020726
US 2003068759	A1	20030410	US 2002-206920	20020726
US 2003068760	A1	20030410	US 2002-206921	20020726
US 2003073183	A1	20030417	US 2002-206917	20020726
US 2003096359	A1	20030522	US 2002-205910	20020726
US 2004048334	A1	20040311	US 2002-205890	20020726
US 2003064467	A1	20030403	US 2002-207921	20020729
US 2003064468	A1	20030403	US 2002-207922	20020729
US 2003064469	A1	20030403	US 2002-208027	20020729
US 2003068765	A1	20030410	US 2002-207916	20020729
US 2003068766	A1	20030410	US 2002-207917	20020729
US 2003068767	A1	20030410	US 2002-207918	20020729
US 2003068768	A1	20030410	US 2002-207919	20020729
US 2003068769	A1	20030410	US 2002-207920	20020729
US 2003068770	A1	20030410	US 2002-207925	20020729
US 2003068771	A1	20030410	US 2002-208021	20020729

US 2003068772	A1	20030410	US 2002-208022	20020729
US 2003068773	A1	20030410	US 2002-208023	20020729
US 2003068774	A1	20030410	US 2002-208026	20020729
US 2003068775	A1	20030410	US 2002-208029	20020729
US 2003068776	A1	20030410	US 2002-208030	20020729
US 2003073184	A1	20030417	US 2002-207923	20020729
US 2003073185	A1	20030417	US 2002-207924	20020729
US 2003073186	A1	20030417	US 2002-208028	20020729
US 2003104557	A1	20030605	US 2002-208025	20020729
US 2003215912	A1	20031120	US 2002-207915	20020729
US 2004048335	A1	20040311	US 2002-208024	20020729
US 2003120056	A1	20030626	US 2002-289498	20021105
US 2003144498	A1	20030731	US 2002-289527	20021105
US 2004249141	A1	20041209	US 2002-289490	20021105
US 2003224984	A1	20031204	US 2002-305654	20021126
US 2003186306	A1	20031002	US 2003-410374	20030408
US 2003199044	A1	20031023	US 2003-410552	20030408
AU 2003248191	A1	20031106	AU 2003-248191	20030919
AU 2003257515	A1	20031120	AU 2003-257515	20031023
AU 2003259607	A1	20031127	AU 2003-259607	20031031
US 2004258710	A1	20041223	US 2004-791618	20040302
US 2006019307	A1	20060126	US 2004-795482	20040309
US 2006210991	A1	20060921	US 2004-795503	20040309
US 2005100544	A1	20050512	US 2004-886040	20040708
US 2007003545	A9	20070104		
US 2005019823	A1	20050127	US 2004-931886	20040831
US 2005153396	A1	20050714	US 2004-955952	20040929
US 2005153348	A1	20050714	US 2004-20604	20041221
US 2005176041	A1	20050811	US 2004-26279	20041230
US 2005214819	A1	20050929	US 2005-30464	20050105
US 2005164266	A1	20050728	US 2005-36582	20050113
US 2005170396	A1	20050804	US 2005-36869	20050114
US 2005202475	A1	20050915	US 2005-38328	20050118
US 2006246461	A1	20061102	US 2005-38549	20050118
US 2006068404	A1	20060330	US 2005-39623	20050119
US 2005244852	A1	20051103	US 2005-40638	20050121
US 2005272058	A1	20051208	US 2005-42889	20050124
US 2005176046	A1	20050811	US 2005-46650	20050128
US 2005176104	A1	20050811	US 2005-52503	20050204
US 2005136515	A1	20050623	US 2005-56802	20050211
US 2005136475	A1	20050623	US 2005-60652	20050216
US 2005164279	A1	20050728	US 2005-60240	20050216
US 2005260622	A1	20051124	US 2005-67573	20050225
JP 2005224245	A	20050825	JP 2005-54646	20050228
US 2005250136	A1	20051110	US 2005-78280	20050310
US 2005158830	A1	20050721	US 2005-80062	20050314
US 2005260632	A1	20051124	US 2005-84458	20050316
US 2006051777	A1	20060309	US 2005-84792	20050318
US 2006068413	A1	20060330	US 2005-90729	20050325
JP 2005245460	A	20050915	JP 2005-118817	20050415
JP 2005253468	A	20050922	JP 2005-118579	20050415
JP 2005253469	A	20050922	JP 2005-118701	20050415
JP 2005261437	A	20050929	JP 2005-119030	20050415
JP 2005270107	A	20051006	JP 2005-118968	20050415
US 2005214846	A1	20050929	US 2005-117757	20050427
US 2006003355	A1	20060105	US 2005-122524	20050504
US 2005266461	A1	20051201	US 2005-124327	20050506
US 2006040289	A1	20060223	US 2005-149801	20050609
US 2006051783	A1	20060309	US 2005-150463	20050609
US 2006051784	A1	20060309	US 2005-150758	20050609
US 2006084084	A1	20060420	US 2005-150881	20050609
US 2006051785	A1	20060309	US 2005-151868	20050613
US 2006019287	A1	20060126	US 2005-172714	20050628
US 2006088854	A1	20060427	US 2005-190075	20050725

US 2006246465	A1	20061102	US 2005-189442	20050725
US 2006194219	A1	20060831	US 2005-194054	20050728
US 2006068423	A1	20060330	US 2005-199816	20050808
US 2006029966	A1	20060209	US 2005-216875	20050826
AU 2005205752	A1	20050922	AU 2005-205752	20050831
AU 2005205754	A1	20050922	AU 2005-205754	20050831
AU 2005205755	A1	20050922	AU 2005-205755	20050831
AU 2005205758	A1	20050922	AU 2005-205758	20050831
US 2006246540	A1	20061102	US 2005-240891	20050929
US 2006167231	A1	20060727	US 2005-258349	20051024
US 2006127983	A1	20060615	US 2005-296155	20051206
JP 2006104212	A	20060420	JP 2005-363921	20051216
US 2006194283	A1	20060831	US 2006-341175	20060127
JP 2006223304	A	20060831	JP 2006-24604	20060201
US 2006188914	A1	20060824	US 2006-369228	20060302
US 2006257897	A1	20061116	US 2006-367172	20060302
US 2006183169	A1	20060817	US 2006-407991	20060421
PRIORITY APPLN. INFO.:			WO 2000-US5601	W 20000301
			WO 2000-US5841	W 20000302
			US 2000-187202P	P 20000303
			US 2000-186968P	P 20000306
			US 2000-189320P	P 20000314
			US 2000-189328P	P 20000314
			WO 2000-US6884	W 20000315
			US 2000-190828P	P 20000321
			US 2000-191007P	P 20000321
			US 2000-191048P	P 20000321
			US 2000-191314P	P 20000321
			US 2000-192655P	P 20000328
			US 2000-193032P	P 20000329
			US 2000-193053P	P 20000329
			WO 2000-US8439	W 20000330
			US 2000-194449P	P 20000404
			US 2000-194647P	P 20000404
			US 2000-195975P	P 20000411
			US 2000-196000P	P 20000411
			US 2000-196187P	P 20000411
			US 2000-196690P	P 20000411
			US 2000-196820P	P 20000411
			US 1997-63128P	P 19971024
			US 1997-63541P	P 19971028
			US 1997-63564P	P 19971028
			US 1997-63870P	P 19971031
			US 1997-66120P	P 19971121
			US 1997-67411P	P 19971203
			US 1997-69278P	P 19971211
			US 1997-69334P	P 19971211
			US 1997-69335P	P 19971211
			US 1997-69425P	P 19971212
			US 1997-69694P	P 19971216
			US 1997-69696P	P 19971216
			US 1997-69702P	P 19971216
			US 1997-69870P	P 19971217
			US 1997-69873P	P 19971217
			US 1997-68017P	P 19971218
			US 1998-70440P	P 19980105
			US 1998-74086P	P 19980209
			US 1998-74092P	P 19980209
			US 1998-75945P	P 19980225
			US 1998-81071P	P 19980408
			US 1998-82568P	P 19980421
			US 1998-82704P	P 19980422
			US 1998-83742P	P 19980430
			US 1998-84366P	P 19980505

US 1998-84639P	P 19980507
US 1998-85339P	A1 19980513
US 1998-85579P	P 19980515
US 1998-85697P	P 19980515
US 1998-87098P	P 19980528
US 1998-87106P	P 19980528
US 1998-88033P	P 19980604
US 1998-88326P	P 19980604
US 1998-88202P	P 19980605
US 1998-88217P	P 19980605
US 1998-88655P	P 19980609
US 1998-89512P	P 19980616
US 1998-89908P	P 19980618
US 1998-89947P	P 19980619
US 1998-90435P	P 19980624
US 1998-90535P	P 19980624
US 1998-90540P	P 19980624
US 1998-90676P	P 19980625
US 1998-90678P	P 19980625
US 1998-90696P	P 19980625
US 1998-105413	B1 19980626
US 1998-91544P	P 19980701
US 1998-91478P	P 19980702
US 1998-91626P	P 19980702
US 1998-91982P	P 19980707
US 1998-94651P	A1 19980730
US 1998-96867P	P 19980817
US 1998-97022P	P 19980818
US 1998-97955P	P 19980826
US 1998-97974P	P 19980826
US 1998-98014P	P 19980826
US 1998-98821P	P 19980902
AU 1998-93881	A3 19980914
WO 1998-US19330	A 19980916
US 1998-101068P	P 19980918
US 1998-101922P	P 19980924
US 1998-102487P	P 19980930
AU 1998-93178	A3 19981002
US 1998-103258P	P 19981006
US 1998-168978	B1 19981007
WO 1998-US21141	A 19981007
US 1998-105169P	P 19981022
US 1998-105882P	P 19981027
US 1998-106033P	P 19981028
US 1998-63561P	P 19981028
US 1998-187368	A1 19981106
WO 1998-US25108	A 19981201
US 1998-202054	A1 19981207
US 1998-112514P	P 19981215
US 1998-112850P	P 19981216
US 1998-216021	B1 19981216
US 1998-113296P	P 19981222
US 1998-113300P	P 19981222
US 1998-218517	B1 19981222
US 1998-113430P	P 19981223
US 1998-113605P	P 19981223
US 1998-113621P	P 19981223
US 1998-114140P	P 19981223
US 1999-115552P	P 19990112
US 1999-116843P	P 19990122
US 1999-254311	A1 19990303
AU 1999-30721	A3 19990308
WO 1999-US5028	A 19990308
US 1999-123618P	P 19990310

US 1999-123957P	P	19990312
US 1999-125774P	P	19990323
US 1999-125775P	P	19990323
US 1999-125778P	P	19990323
US 1999-125826P	P	19990324
US 1999-127035P	P	19990331
US 1999-127706P	P	19990405
US 1999-128849P	P	19990412
US 1999-129122P	P	19990413
US 1999-292404	A1	19990414
WO 1999-US8615	W	19990420
US 1999-130359P	P	19990421
US 1999-131270P	P	19990427
US 1999-131272P	P	19990427
US 1999-131291P	P	19990427
US 1999-131293P	P	19990427
US 1999-131445P	P	19990428
US 1999-132371P	P	19990504
US 1999-132379P	P	19990504
US 1999-132383P	P	19990504
US 1999-133459P	P	19990511
US 1999-134287P	P	19990514
US 1999-311832	A1	19990514
WO 1999-US10733	W	19990514
US 1999-135750P	P	19990525
WO 1999-US12252	W	19990602
US 1999-138166P	P	19990608
US 1999-140650P	P	19990622
US 1999-144758P	P	19990720
US 1999-144791P	P	19990720
US 1999-145698P	P	19990726
US 1999-146222P	P	19990728
US 1999-146970P	P	19990803
US 1999-149268P	P	19990817
US 1999-149395P	P	19990817
US 1999-149411P	P	19990817
US 1999-149413P	P	19990817
US 1999-380137	A1	19990825
US 1999-380138	A1	19990825
US 1999-380139	B1	19990825
US 1999-380142	B1	19990825
US 1999-151689P	P	19990831
US 1999-151736P	P	19990831
US 1999-151791P	P	19990831
US 1999-151792P	P	19990831
WO 1999-US20111	A1	19990901
US 1999-153805P	P	19990914
US 1999-153806P	P	19990914
US 1999-153856P	P	19990914
US 1999-153857P	P	19990914
US 1999-153904P	P	19990914
US 1999-397342	A1	19990915
WO 1999-US21090	A	19990915
CA 1999-2344465	A3	19991005
US 1999-403297	B1	19991018
US 1999-160407P	P	19991019
US 1999-160408P	P	19991019
US 1999-403844	A1	19991027
US 1999-162506P	P	19991029
US 1999-164495P	P	19991109
US 1999-164499P	P	19991109
US 1999-164500P	P	19991109
US 1999-423741	B2	19991110
US 1999-423844	B1	19991112

US 1999-166360P	P 19991116
US 1999-166363P	P 19991116
US 1999-166364P	P 19991116
AU 2000-17482	A3 19991130
WO 1999-US28313	A 19991130
WO 1999-US28409	A 19991130
WO 1999-US28301	A 19991201
AU 2000-17499	A3 19991202
EP 1999-960644	A3 19991202
WO 1999-US28551	W 19991202
WO 1999-US28564	A 19991202
WO 1999-US28565	A1 19991202
US 1999-169495P	P 19991207
US 1999-170262P	P 19991209
WO 1999-US30095	A 19991216
WO 1999-US30911	A 19991220
WO 1999-US30999	A2 19991220
US 1999-468978	A1 19991221
WO 1999-US30720	W 19991222
WO 1999-US31243	A 19991230
WO 1999-US31274	W 19991230
WO 2000-US219	A 20000105
WO 2000-US277	A 20000106
WO 2000-US376	A 20000106
US 2000-175481P	P 20000111
WO 2000-US3565	A 20000211
WO 2000-US4341	A1 20000218
WO 2000-US4342	A1 20000218
WO 2000-US4414	A 20000222
WO 2000-US4914	A 20000224
WO 2000-US5004	A 20000224
WO 2000-US5746	A 20000302
US 2000-522342	B2 20000309
WO 2000-US6471	A2 20000309
WO 2000-US6666	A 20000314
WO 2000-US7377	A2 20000320
US 2000-191015P	P 20000321
WO 2000-US7532	W 20000321
US 2000-548815	B2 20000413
US 2000-198121P	P 20000418
US 2000-198585P	P 20000418
US 2000-199397P	P 20000425
US 2000-199550P	P 20000425
US 2000-199654P	P 20000425
US 2000-201516P	P 20000503
WO 2000-US13358	A2 20000515
US 2000-204675P	P 20000517
WO 2000-US13705	A2 20000517
WO 2000-US14042	A1 20000522
WO 2000-US14941	A 20000530
WO 2000-US15264	W 20000602
US 2000-209832P	P 20000605
US 2000-212901P	P 20000620
US 2000-213807P	P 20000622
US 2000-219556P	P 20000720
US 2000-220585P	P 20000725
US 2000-220605P	P 20000725
US 2000-220607P	P 20000725
US 2000-220624P	P 20000725
US 2000-220638P	P 20000725
US 2000-220664P	P 20000725
US 2000-220666P	P 20000725
US 2000-220893P	P 20000726
WO 2000-US20710	W 20000728

AB The present invention is directed to novel polypeptides and to nucleic acid mols. encoding those polypeptides. Thus, 305 cDNAs encoding human secreted or transmembrane proteins were identified by extracellular domain homol. screening, amylase screening, and signal algorithm anal. These transcripts for these proteins are overexpressed in various cancerous tissues, including adrenal, lung, colon, breast, prostate, rectal, cervical, and liver tumors. Certain of the proteins stimulate release of tumor necrosis factor- α from human blood, and also stimulate proliferation or differentiation of chondrocytes. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide mols. comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

IT 221079-13-6

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(amino acid sequence; secreted and transmembrane polypeptides and human nucleic acids encoding them that are overexpressed in cancerous tissues)

RN 221079-13-6 CAPLUS

CN Dipeptidase, acetylasparylglutamate (human clone P1-683/P1-1694 reduced) (9CI) (CA INDEX NAME)

```

SEQ      1 MWNLLHETDS AVATARRPRW LCAGALVLAG GFFLLGFLFG WFIKSSNEAT
        51 NITPKHNMKA FLDELKAENI KKFLHNFTQI PHLAGTEQNF QLAKQIQSQW
       101 KEFGLDSVEL AHYDVLLSYP NKTHPNYISI INEDGNEIFN TSLFEP PPPG
       151 YENVSDIVPP FSAFSPQGMP EGDLVVYVNYA RTEDFFKLER DMKINC SGKI
       201 VIARYGKVFR GNKVNAQLA GAKGVILYSD PADYFAPGVK SYPDGNWLP
       251 GGVQRGNILN LNGAGDPLTP GYPANEYAYR RGIAEAVGLP SIPVHPIGYY
       301 DAQKLEKMG GSAPPDSSWR GSLKVPYNVG PGFTGNFSTQ KVKMHIHSTN
       351 EVTRIYNVIG TLRGAVEPDR YVILGGHRDS WVFGGIDPQS GAAVVHEIVR
       401 SFGTLKKEGW RPRRTILFAS WDAEEFGLLG STEWAEENSR LLQERGVAYI
       451 NADSSIEGNY TLRVDCTPLM YSLVHNLTKE LKSPDEGFEG KSLYESWTKK
       501 SPSPEFSGMP RISKLGSGND FEVFFQRLGI ASGRARYTKN WETNKFSGYP
       551 LYHSVYETYE LVEKFYDPMF KYHLTVAQVR GGMVFELANS IVLPFDCRDY
       601 AVVLRKYADK IYSISMKHPQ EMKTYSVSFD SLFSVKNFT EIASKFSERL
       651 QDFDKSNPIV LRMMNDQLMF LERAFIDPLG LPDRPFYRHV IYAPSSH NKY
       701 AGESFPGIYD ALFDIESKVD PSKAWGEVKR QIYVAAFTVQ AAAETLSEVA

```

L5 ANSWER 6 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:472510 CAPLUS

DOCUMENT NUMBER: 135:75731

TITLE: Identification of HLA binding motifs of prostate cancer antigens for induction of tumor immunity

INVENTOR(S): Fikes, John; Sette, Alessandro; Sidney, John; Southwood, Scott; Chesnut, Robert; Celis, Esteban; Keogh, Elissa

PATENT ASSIGNEE(S): Epimmune Inc., USA

SOURCE: PCT Int. Appl., 252 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2001045728 A2 20010628 WO 2000-US35516 20001220 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2394741 A1 20010628 CA 2000-2394741 20001220 <--
AU 2001026055 A5 20010703 AU 2001-26055 20001220 <--
EP 1244465 A1 20021002 EP 2000-989560 20001220 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2003521245 T 20030715 JP 2001-546667 20001220
US 2004037843 A1 20040226 US 2003-168507 20030114
PRIORITY APPLN. INFO.: US 1999-171312P P 19991221
US 2000-633364 A 20000807
WO 2000-US35516 W 20001220
AB The authors disclose motifs and supermotifs for binding to HLA class I and
class II mols. of peptide epitopes derived from prostate cancer antigens.
The motif-bearing peptides demonstrate immunogenicity for cytotoxic
T-cells and helper T-cells to the cognate antigens.
IT 149200-79-3
RL: PRP (Properties)
(unclaimed sequence; identification of HLA binding motifs of prostate
cancer antigens for induction of tumor immunity)
RN 149200-79-3 CAPLUS
CN Glycoprotein PSM (human clone 55A prostate-specific reduced) (9CI) (CA
INDEX NAME)

SEQ 1 MWNLLHETDS AVATARRPRW LCAGALVLG GFFLLGFLFG WFIKSSNEAT
51 NITPKHNMKA FLDELKAENI KKFLYNFTQI PHLAGTEQNF QLAKQIQSQW
101 KEFGLDSEVL AHYDVLLSYP NKTHPNYISI INEDGNEIFN TSLFEP PPPG
151 YENVSDIVPP FSAFSPQGM EGDLYVNYA RTEDFFKLER DMKINCSGKI
201 VIARYGKVFR GNKVKNAQLA GAKGVILYSD PADYFAPGVK SYPDGWNLP
251 GGVQRGNILN LNGAGDPLTP GYPANEYAYR RGIAEAVGLP SIPVHPIGYY
301 DAQKLLEKMG GSAPPDSSWR GSLKVPYNVG PGFTGNFSTQ KVKMHIHSTN
351 EVTRIYNVIG TLRGAVEPDR YVILGGHRDS WVFGGIDPQS GAAVVHEIVR
401 SFGTLKKEGW RPRRTILFAS WDAEEFGLLG STEWAEENSR LLQERGVAI
451 NADSSIEGNY TLRVDCTPLM YSLVHNLTK LKSPDEGFEG KSLYESWTKK
501 SPSPEFSGMP RISKLGSGND FEVFFQRLGI ASGRARYTKN WETNKFSGYP
551 LYHSVYETYE LVEKFYDPMF KYHLTVAQVR GGMVFELANS IVLPFDCRDY
601 AVVLRKYADK IYSISMKHPQ EMKTYSVSFD SLFSAVKNFT EIASKFSERL
651 QDFDKSNPIV LRMMNDQLMF LERAFIDPLG LPDRPFYRHV IYAPSSH NKY
701 AGESFPGIYD ALFDIESKVD PSKAWGEVKR QIYVAAFTVQ AAAETLSEVA

L5 ANSWER 10 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:821601 CAPLUS
DOCUMENT NUMBER: 134:4046
TITLE: Monoclonal antibodies specific for the extracellular
domain of prostate-specific membrane antigen
INVENTOR(S): Murphy, Gerald P.; Boynton, Alton L.; Holmes, Eric H.;
Tino, William Thomas
PATENT ASSIGNEE(S): Northwest Biotherapeutics, Inc., USA
SOURCE: U.S., 39 pp., Cont.-in-part of U. S. Ser. No. 827,017,
abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6150508	A	20001121	US 1998-44668	19980318 <--
CA 2323096	A1	19990923	CA 1999-2323096	19990318 <--
CA 2323096	C	20041019		
WO 9947554	A1	19990923	WO 1999-US5864	19990318 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9931896	A	19991011	AU 1999-31896	19990318 <--
AU 768558	B2	20031218		
EP 1064303	A1	20010103	EP 1999-913932	19990318 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002506629	T	20020305	JP 2000-536745	19990318 <--
US 6962981	B1	20051108	US 2000-561502	20000428
US 2004024188	A1	20040205	US 2003-428360	20030501
PRIORITY APPLN. INFO.:			US 1996-621399	B2 19960325
			US 1997-827017	B2 19970325
			US 1998-44668	A 19980318
			WO 1999-US5864	W 19990318
			US 2000-561502	A1 20000428
AB	The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Addnl., the present invention relates to a novel protein variant (PSM') of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM' allows the use of an immunoenzymic assay for their detection.			
IT	149200-79-3 177571-74-3 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (amino acid sequence; monoclonal antibodies specific to extracellular domain of prostate-specific membrane antigen PSM' variant for diagnosis and prognosis of prostate cancer)			
RN	149200-79-3 CAPLUS			
CN	Glycoprotein PSM (human clone 55A prostate-specific reduced) (9CI) (CA INDEX NAME)			
SEQ	1 MWNLLHETDS AVATARRPRW LCAGALVLAG GFFLLGFLFG WFIKSSNEAT 51 NITPKHNMKA FLDELKAENI KKFLYNFTQI PHLAGTEQNF QLAKQIQSQW 101 KEFGLDSVEL AHYDVLLSYP NKTHPNYISI INEDGNEIFN TSLFEP PPPG 151 YENVSDIVPP FSAFSPQGM EGD LVYVNYA RTEDFFKLER DMKINCSGKI 201 VIARYGKVFR GNKVNAQLA GAKGVILYSD PADYFAPGVK SYPDGWNLP 251 GGVQRGNILN LNGAGDPLTP GYPANEYAYR RGIAEAVGLP SIPVHPIGYY 301 DAQKLLEKMG GSAPPDSSWR GSLKVPYNVG PGFTGNFSTQ KVKMHIHSTN 351 EVTRIYNVIG TLRGAVEPDR YVILGGHRDS WVFGGIDPQS GAADVHEIVR 401 SFGTLKKEGW RPRRTILFAS WDAEEFGLLG STEWAEENSR LLQERGVAYI 451 NADSSIEGNY TLRVDCTPLM YSLVHNLTKE LKSPDEGFEG KSLYESWTKK 501 SPSPEFSGMP RISKLGSGND FEVFFQRLGI ASGRARYTKN WETNKFSGYP 551 LYHSVYETYE LVEKFYDPMF KYHLTVAQVR GGMVFELANS IVLPFDCRDY 601 AVVLRKYADK IYSISMKHPQ EMKTYSVSFD SLFSAVKNFT EIASKFSERL			

651 QDFDKSNPIV LRMMNDQLMF LERAFIDPLG LPDRPFYRHV IYAPSSHNKY
701 AGESFPGIYD ALFDIESKVD PSKAWGEVKR QIYVAAFTVQ AAAETLSEVA

RN 177571-74-3 CAPLUS
CN Antigen PSMA (prostate-specific membrane antigen) (human extracellular domain-containing fragment) (9CI) (CA INDEX NAME)

SEQ 1 KSSNEATNIT PKHNMKAFLD ELKAENIKKF LYNFTQIPHL AGTEQNFQLA
51 KQIQSQWKEF GLDSVELAHY DVLLSYPNKT HPNYISIINE DGNEIFNTSL
101 FEPPPPGYEN VSDIVPPFSA FSPQGMPEGD LVYVNYARTE DFFKLERDMK
151 INCSGKIVIA RYGVFVRGNK VKNAQLAGAK GVILYSDPAD YFAPGVKSYP
201 DGWNLPGGGV QRGNILNLNG AGDPLTPGYP ANEYAYRRGI AEAVGLPSIP
251 VHPIGYYDAQ KLEKMGGSA PPDSSWRGSL KVPYNVGPFG TGNFSTQKVK
301 MHIHSTNEVT RIYNVIGTLR GAVEPDRYVI LGGHRDSWVF GGIDPQSGAA
351 VVHEIVRSFG TLKKEGWRPR RTILFASWDA EEFGLLGSTE WAEENSRLLO
401 ERGVAYINAD SSIEGNYTLR VDCTPLMYSL VHNLTKEKLS PDEGFEGKSL
451 YESWTKKSPS PEFSGMPRIS KLGSGNDFEV FFQRLGIASG RARYTKNWET
501 NKFSGYPLYH SVYETYELVE KFYDPMFKYH LTVAQVRGGM VFELANSIVL
551 PFDCRDYAVV LRKYADKIYS ISMKHPQEMK TYSVSFDSL F SAVKNFTEIA
601 SKFSERLQDF DKSNIPIVLRM MNDQLMFLE AFIDPLGLPD RPFYRHVIYA
651 PSSHNKYAGE SFPGIYDALF DIESKVDPSK AWGEVKRQIY VAAFTVQAAA
701 ETLSEVA

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:755108 CAPLUS

DOCUMENT NUMBER: 135:13933

TITLE: Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer

AUTHOR(S): O'Keefe, Denise S.; Uchida, Atsushi; Bacich, Dean J.; Watt, Fujiko B.; Martorana, Anna; Molloy, Peter L.; Heston, Warren D. W.

CORPORATE SOURCE: George M. O'Brien Urology Research Center, Department of Cancer Biology, Cleveland Clinic Foundation, Lerner Research Institute, Cleveland, OH, 44195, USA

SOURCE: Prostate (New York) (2000), 45(2), 149-157
CODEN: PRSTD5; ISSN: 0270-4137

PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Prostate-specific membrane antigen (PSMA) is abundantly expressed in virtually 100% of prostate cancers and metastases. In addition, unlike prostate-specific antigen (PSA), PSMA is upregulated under conditions of androgen deprivation. Therefore, PSMA is an attractive therapeutic target for advanced prostate cancer. Recently, both the promoter and the enhancer driving prostate-specific expression of the PSMA gene were cloned. The authors describe here the anal. of the PSMA enhancer for the most active region(s) and present a way of using the enhancer in combination with the E. coli cytosine deaminase gene for suicide-driven gene therapy that converts the nontoxic prodrug 5-fluorocytosine (5-FC) into the cytotoxic drug 5-fluorouracil (5-FU) in prostate cancer cells. Deletion constructs of the full-length PSMA enhancer were subcloned into a luciferase reporter vector containing either the PSMA or SV-40 promoter. The most active portion of the enhancer was then determined via luciferase activity in the C4-2 cell line. The authors then replaced the luciferase gene with the E. coli cytosine deaminase gene in the subclone that showed the most

luciferase activity. The specificity of this technique was examined in vitro, using the prostate cancer cell line LNCaP, its androgen-independent derivative C4-2, and a number of nonprostatic cell lines. The toxicity of 5-FC and 5-FU on transiently transfected cell lines was then compared. The enhancer region originally isolated from the PSMA gene was approx. 2 kb. Deletion constructs revealed that at least 2 distinct regions seem to contribute to expression of the gene in prostate cancer cells, and therefore the best construct for prostate specific expression was determined to be 1,648 bp long. The IC50 of 5-FC was similar in all cell lines tested (> 10 mM). However, transfection with the 1648 nt PSMA enhancer and the PSMA promoter to drive the cytosine deaminase gene enhanced toxicity in a dose-dependent manner more than 50-fold, while cells that did not express the PSMA gene were not significantly sensitized by transfection. Suicide gene therapy using the PSMA enhancer may be of benefit to patients who have undergone androgen ablation therapy and are suffering a relapse of disease.

IT 221079-13-6

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer)

RN 221079-13-6 CAPLUS

CN Dipeptidase, acetylasparylglutamate (human clone P1-683/P1-1694 reduced) (9CI) (CA INDEX NAME)

```
SEQ      1 MWNLLHETDS AVATARRPRW LCAGALVLAG GFFLLGFLFG WFIKSSNEAT
        51 NITPKHNMKA FLDELKAENI KKFLHNFTQI PHLAGTEQNF QLAKQIQSQW
       101 KEFGLDSVEL AHYDVLLSYP NKTHPNYISI INEDGNEIFN TSLFEPPPPG
       151 YENVSDIVPP FSAFSPQGMP EGDLVYVNYA RTEDFFKLER DMKINCSGKI
       201 VIARYGKVFR GNKVKNAQLA GAKGVILYSD PADYFAPGVK SYPDGWNLPG
       251 GGVQGRNILN LNGAGDPLTP GYPANEYAYR RGIAEAVGLP SIPVHPIGYY
       301 DAQKLEKMG GSAPPDSSWR GSLKVPYNVG PGFTGNFSTQ KVKMHIHSTN
       351 EVTRIYNVIG TLRGAVEPDR YVILGGHRDS WVFGGIDPQS GAAVVHEIVR
       401 SFGTLKKEGW RPRRTILFAS WDAEEFGLLG STEWAEENSR LLQERGVAIYI
       451 NADSSIEGNY TLRVDCTPLM YSLVHNLTKE LKSPDEGFEG KSLYESWTKK
       501 SPSPEFSGMP RISKLGSGND FEVFFQRLGI ASGRARYTKN WETNKFSGYP
       551 LYHSVYETYE LVEKFYDPMF KYHLTVAQVR GGMVFELANS IVLPFDCRDY
       601 AVVLRKYADK IYSISMKHPQ EMKTYSVSFD SLFSVKNFT EIASKFSERL
       651 QDFDKSNPIV LRMMNDQLMF LERAFIDPLG LPDRPFYRHV IYAPSSHNKY
       701 AGESFPGIYD ALFDIESKVD PSKAWGEVKR QIYVAAFTVQ AAAETLSEVA
```

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:742114 CAPLUS

DOCUMENT NUMBER: 133:291987

TITLE: Protein and cDNA sequences of the human prostate-specific membrane antigen-like gene and diagnostic and therapeutic uses thereof

INVENTOR(S): Heston, Warren D. W.; O'Keefe, Denise S.

PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2000061605 A1 20001019 WO 2000-US9417 20000407 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2370033 A1 20001019 CA 2000-2370033 20000407 <--
EP 1177207 A1 20020206 EP 2000-921932 20000407 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
AU 774697 B2 20040701 AU 2000-42189 20000407
US 6897062 B1 20050524 US 2001-973382 20011009
US 2005064504 A1 20050324 US 2004-990840 20041117
PRIORITY APPLN. INFO.: US 1999-128839P P 19990409
WO 2000-US9417 W 20000407
US 2001-973382 A3 20011009

AB The present invention discloses protein and cDNA sequences a novel human gene, termed PSMA-like, that is very similar to the prostate-specific membrane antigen (PSMA) gene and cross-reacts with current detection methods for PSMA. The PSMA-like gene that has been mapped to human chromosome 11q, encodes a new protein that has NAALADase activities. The present invention also provides for a method of distinguishing the PSMA and PSMA-like mRNAs and/or proteins for diagnostic and therapeutic strategies that desire specific targeting of either the PSMA or PSMA-like gene.

IT 301456-02-0

RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses) (amino acid sequence; protein and cDNA sequences of human prostate-specific membrane antigen-like gene and diagnostic and therapeutic uses thereof)

RN 301456-02-0 CAPLUS

CN Protein PSMA-like (human live prostate-specific membrane antigen-like gene) (9CI) (CA INDEX NAME)

SEQ 1 MGGSAPPDSS WRGSLKVSYN VPGGFTGNFS TQKVKMHIHS TNEVTRIYNV
51 IGTLRGAVEP DRYVILGGHR DSWVFGGIDP QSGAAVVHET VRSFGTLKKE
101 GWRPRRTILF ASWDAEEFGL LGSTEWAE DN S RLLQERGVA YINADSSIEG
151 NYTLRVDCTP LMYSLVYNLT KELKSPDEGF EGKSLYESWT KKSPSPFEFSG
201 MPRISKLGSG NDFEVFFQRI GIASGRARYT KNWETNKFSG YPLYLSVYET
251 YELVEKFYDP MFKYHLTVAQ VRGGMVFELA NSIVLPFDCR DYAVVLRKYA
301 DKIYNISMKH PQEMKTYSL S FDSLFSVKN FTEIASKFSE RLQDFDKSNP
351 ILLRMMNDQL MFLERAFIDP LGLPDRPFYR HVIYAPSSH N KYAGESFPGI
401 YDALFDIESK VDPSKAWGDV KRQISVAAFT VQAAAETLSE VA

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:613955 CAPLUS

DOCUMENT NUMBER: 131:241983

TITLE: Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen

INVENTOR(S): Murphy, Gerald P.; Boynton, Alton L.; Holmes, Eric H.; Tino, William Thomas

PATENT ASSIGNEE(S): Northwest Biotherapeutics, Inc., USA

SOURCE: PCT Int. Appl., 97 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9947554	A1	19990923	WO 1999-US5864	19990318 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6150508	A	20001121	US 1998-44668	19980318 <--
CA 2323096	A1	19990923	CA 1999-2323096	19990318 <--
CA 2323096	C	20041019		
AU 9931896	A	19991011	AU 1999-31896	19990318 <--
AU 768558	B2	20031218		
EP 1064303	A1	20010103	EP 1999-913932	19990318 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002506629	T	20020305	JP 2000-536745	19990318 <--
PRIORITY APPLN. INFO.:				
			US 1998-44668	A 19980318
			US 1996-621399	B2 19960325
			US 1997-827017	B2 19970325
			WO 1999-US5864	W 19990318

AB The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Addnl., the present invention relates to a novel protein variant (PSM') of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM' allows the use of an immunoenzymic assay for their detection.

IT 149200-79-3 177571-74-3

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (amino acid sequence; monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen and hybridomas for diagnosis and treatment of prostate cancer)

RN 149200-79-3 CAPLUS

CN Glycoprotein PSM (human clone 55A prostate-specific reduced) (9CI) (CA INDEX NAME)

SEQ 1 MWNLLHETDS AVATARRPRW LCAGALVLAG GFFLLGFLFG WFIKSSNEAT
 51 NITPKHNMKA FLDELKAENI KKFLYNFTQI PHLAGTEQNF QLAKQIQSQW
 101 KEFGLDSVEL AHYDVLLSYP NKTHPNYISI INEDGNEIFN TSLFEPPPPG
 151 YENVSDIVPP FSAFSPQGM EGD LVYVNYA RTEDFFKLER DMKINCSGKI
 201 VIARYGKVFR GNKVKNQALA GAKGVILYSD PADYFAPGVK SYPDGWNLP
 251 GGVQRGNILN LNGAGDPLTP GYPANEYAYR RGIAEAVGLP SIPVHPIGYY
 301 DAQKLLKMG GSAPPDSSWR GSLKVPYNVG PGFTGNFSTQ KVKMHIHSTN
 351 EVTRIYNVIG TLRGAVEPDR YVILGGHRDS WVFGGIDPQS GAAVVHEIVR
 401 SFGTLKKEGW RPRRTILFAS WDAEEFGLLG STEWAEENSR LLQERGVAYI
 451 NADSSIEGNY TLRVDCTPLM YSLVHNLTKE LKSPDEGFEG KSLYESWTKK
 501 SPSPEFSGMP RISKLGSGND FEVFFQRLGI ASGRARYTKN WETNKFSGYP
 551 LYHSVYETYE LVEKFYDPMF KYHLTVAQVR GGMVFELANS IVLPFDCRDY
 601 AVVLRKYADK IYSISMKHPQ EMKTYSVSFD SLFSAVKNFT EIASKFSERL

651 QDFDKSNPIV LRMMNDQLMF LERAFIDPLG LPDRPFYRHV IYAPSSHNKY
701 AGESFPGIYD ALFDIESKVD PSKAWGEVKR QIYVAAFTVQ AAAETLSEVA

RN 177571-74-3 CAPLUS
CN Antigen PSMA (prostate-specific membrane antigen) (human extracellular domain-containing fragment) (9CI) (CA INDEX NAME)

SEQ 1 KSSNEATNIT PKHNMKAFLD ELKAENIKKF LYNFTQIPHL AGTEQNFQLA
51 KQIQSQWKEF GLDSVELAHY DVLLSYPNKT HPNYISIINE DGNEIFNTSL
101 FEPPPPGYEN VSDIVPPFSA FSPQGMPEGD LVYVNYARTE DFFKLERDMK
151 INCSGKIVIA RYGVFVRGNK VKNAQLAGAK GVILYSDPAD YFAPGVKSYP
201 DGWNLPGGGV QRGNILNLNG AGDPLTPGYP ANEYAYRRGI AEAVGLPSIP
251 VHPIGYYDAQ KLEKMGGS A PDSSWRGSL KVPYNVGPFG TGNFSTQKVK
301 MHIHSTNEVT RIYNVIGTLR GAVEPDYVI LGGHRDSWVF GGIDPQSGAA
351 VVHEIVRSFG TLKKEGWRPR RTILFASWDA EEFGLLGSTE WAEENSRLLO
401 ERGVAYINAD SSIEGNYTLR VDCTPLMYSL VHNLTKEKLS PDEGFEGKSL
451 YESWTKKSPS PEFSGMPRIS KLGSGNDFEV FFQRLGIASG RARYTKNWET
501 NKFSGYPLYH SVYETYELVE KFYDPMFKYH LTVAQVRGGM VFELANSIVL
551 PFDCRDYAVV LRKYADKIYS ISMKHPQEMK TYSVSFDSL F SAVKNFTEIA
601 SKFSERLQDF DKSNIPLVRM MNDQLMFLE AFIDPLGLPD RPFYRHVIYA
651 PSSHNKYAGE SFPGIYDALF DIESKVDPSK AWGEVKRQIY VAAFTVQAAA
701 ETLSEVA

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:766631 CAPLUS

DOCUMENT NUMBER: 130:218945

TITLE: Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene

AUTHOR(S): O'Keefe, Denise S.; Su, Sai L.; Bacich, Dean J.; Horiguchi, Yutaka; Luo, Ying; Powell, C. Thomas; Zandvliet, Dorothea; Russell, Pamela J.; Molloy, Peter L.; Nowak, Norma J.; Shows, Thomas B.; Mullins, Cami; Vonder Haar, Raymond A.; Fair, William R.; Heston, Warren D. W.

CORPORATE SOURCE: Sloan-Kettering Institute for Cancer Research, Molecular Pharmacology and Therapeutics Division, Urologic Oncology Research Laboratory, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA

SOURCE: Biochimica et Biophysica Acta, Gene Structure and Expression (1998), 1443(1-2), 113-127
CODEN: BBGSD5; ISSN: 0167-4781

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Prostate-specific membrane antigen (PSMA) is a 100 kDa type II transmembrane protein with folate hydrolase and NAALAdase activity. PSMA is highly expressed in prostate cancer and the vasculature of most solid tumors, and is currently the target of a number of diagnostic and therapeutic strategies. PSMA is also expressed in the brain, and is involved in conversion of the major neurotransmitter NAAG (N-acetyl-aspartyl glutamate) to NAA and free glutamate, the levels of which are disrupted in several neurol. disorders including multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease and schizophrenia. To facilitate anal. of the role of PSMA in carcinoma we have determined the structural organization of the gene. The gene consists of 19 exons spanning approx.

60 kb of genomic DNA. A 1244 nt portion of the 5' region of the PSMA gene was able to drive the firefly luciferase reporter gene in prostate but not breast-derived cell lines. We have mapped the gene encoding PSMA to 11p11-p12, however a gene homologous, but not identical, to PSMA exists on chromosome 11q14. Anal. of sequence differences between non-coding regions of the two genes suggests duplication and divergence occurred 22 million years ago.

IT 221079-13-6

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; mapping, genomic organization and promoter anal. of the human prostate-specific membrane antigen (PSMA) gene, PSMA antigen displays folate hydrolase and NAALAdase activity)

RN 221079-13-6 CAPLUS

CN Dipeptidase, acetylaspartylglutamate (human clone P1-683/P1-1694 reduced) (9CI) (CA INDEX NAME)

SEQ 1 MWNLLHETDS AVATARRPRW LCAGALVLAG GFFLLGFLFG WFIKSSNEAT
51 NITPKHNMKA FLDELKAENI KKFLHNFTQI PHLAGTEQNF QLAKQIQSQW
101 KEFGLDSVEL AHYDVLLSYP NKTHPNYISI INEDGNEIFN TSLFEP PPPG
151 YENVSDIVPP FSAFSPQGM EGD LVYVNYA RTEDFFKLER DMKINCSGKI
201 VIARYGKVFR GNKVKNAQLA GAKGVILYSD PADYFAPGVK SYPDGWNLP
251 GGVQRGNILN LNGAGDPLTP GYPANEYAYR RGIAEAVGLP SIPVHPIGYY
301 DAQKLLEKMG GSAPPDSSWR GSLKVPYNVG PGFTGNFSTQ KVKMHIHSTN
351 EVTRIYNVIG TLRGAVEPDR YVILGGHRDS WVFGGIDPQS GAAVVHEIVR
401 SFGTLKKEGW RPRRTILFAS WDAEEFGLLG STEWAEENSR LLQERGVAYI
451 NADSSIEGNY TLRVDCTPLM YSLVHNLTKE LKSPDEGFEG KSLYESWTKK
501 SPSPEFSGMP RISKLGSGND FEVFFQRLGI ASGRARYTKN WETNKFSGYP
551 LYHSVYETYE LVEKFYDPMF KYHLTVAQVR GGMVFELANS IVLPFDCRDY
601 AVVLRYADK IYSISMKHPQ EMKTYSVSFD SLFSVKNFT EIASKF SERL
651 QDFDKSNPIV LRMMNDQLMF LERAFIDPLG LPDRPFYRHV IYAPSSH NKY
701 AGESFPGIYD ALFDIESKVD PSKAWGEVKR QIYVAAFTVQ AAAETLSEVA

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:628566 CAPLUS

DOCUMENT NUMBER: 125:272758

TITLE: Prostate-specific membrane (PSM) antigen alternatively spliced form, gene promoter sequence, and prostate cancer PCR diagnosis and treatment with peptide derivs.

INVENTOR(S): Israeli, Ron S.; Heston, Warren D. W.; Fair, William R.

PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA; Israeli Ron S

SOURCE: PCT Int. Appl., 283 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 9626272	A1	19960829	WO 1996-US2424	19960223 <--
W: AU, CA, JP, MX, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5935818	A	19990810	US 1995-394152	19950224 <--
US 6953668	B1	20051011	US 1995-466381	19950602

US 7105159	B1	20060912	US 1995-470735	19950602
CA 2212846	A1	19960829	CA 1996-2212846	19960223 <--
AU 9651725	A	19960911	AU 1996-51725	19960223 <--
AU 717937	B2	20000406		
EP 812356	A1	19971217	EP 1996-908504	19960223 <--
EP 812356	B1	20060208		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 2001526522	T	20011218	JP 1996-525821	19960223 <--
AT 317435	T	20060215	AT 1996-908504	19960223
US 6569432	B1	20030527	US 1996-705477	19960829
US 7037647	B1	20060502	US 1998-894583	19980223
US 2004001846	A1	20040101	US 2003-443694	20030521
US 2004198657	A1	20041007	US 2003-614625	20030702
US 2004253246	A1	20041216	US 2004-751346	20040102
JP 2005036008	A	20050210	JP 2004-256270	20040902
JP 2005052145	A	20050303	JP 2004-256273	20040902
JP 2005185276	A	20050714	JP 2004-256265	20040902

PRIORITY APPLN. INFO.:

US 1995-394152	A	19950224
US 1995-466381	A	19950602
US 1995-470735	A	19950602
US 1992-973337	B2	19921105
WO 1993-US10624	A1	19931105
US 1995-403803	A1	19950317
JP 1996-525821	A3	19960223
WO 1996-US2424	W	19960223
US 1996-705477	A1	19960829

AB The invention provides an isolated mammalian nucleic acid mol. encoding a prostate-specific membrane (PSM) antigen that has been alternatively spliced (PSM'). This invention provides an isolated nucleic acid mol. encoding a prostate-specific membrane antigen promoter. This invention provides a method of detecting hematogenous micrometastatic tumor cells of a subject, and determining prostate cancer progression in a subject. Examples include PSM antigen characterization and carboxypeptidase activity, gene mapping to chromosome 11, and PSM antigen effects on prostate cancer mitogenic response to transferrin. Other examples include nested PCR for blood anal. using PSM antigen gene-derived primers. Lymph Node Carcinoma of Prostate cell line was used to clone the PSM antigen gene. Synthesis of neoplasm inhibitors such as N-phosphonoacetyl aspartyl glutamate derivs. is included.

IT 149200-79-3P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prostate-specific membrane (PSM) antigen alternatively spliced form, gene promoter sequence, and prostate cancer PCR diagnosis and treatment with peptide derivs.)

RN 149200-79-3 CAPLUS

CN Glycoprotein PSM (human clone 55A prostate-specific reduced) (9CI) (CA INDEX NAME)

SEQ 1 MWNLLHETDS AVATARRPRW LCAGALVLAG GFFLLGFLFG WFIKSSNEAT
 51 NITPKHNKKA FLDELKAENI KKFLYNFTQI PHLAGTEQNF QLAKQIQSQW
 101 KEFGLDSVEL AHYDVLLSYP NKTHPNYISI INEDGNEIFN TSLFEP PPPG
 151 YENVSDIVPP FSAFSPQGMF EGDLYVYNYA RTEDFFKLER DMKINCSGKI
 201 VIARYGKVFR GNKVKNAQLA GAKGVILYSD PADYFAPGVK SYPDGWNLP
 251 GGVQRGNILN LNGAGDPLTP GYPANEYAYR RGIAEAVGLP SIPVHPIGYY
 301 DAQKLLKMG GSAPPDSSWR GSLKVPYNVG PGFTGNFSTQ KVKMHIHSTN
 351 EVTRIYNVIG TLRGAVEPDR YVILGGHRDS WVFGGIDPQS GAAVVHEIVR
 401 SFGTLKKEGW RPRRTILFAS WDAEEFGLLG STEWAEENSR LLQERGVAYI
 451 NADSSIEGNY TLRVDCTPLM YSLVHNLTKE LKSPDEGFEG KSLYESWTKK
 501 SPSPEFSGMP RISKLGSGND FEVFFQRLGI ASGRARYTKN WETNKFSGYP
 551 LYHSVYETYE LVEKFYDPMF KYHLTVAQVR GGMVFELANS IVLPFDCRDY
 601 AVVLRKYADK IYSISMKHPQ EMKTYSVSFD SLFSVKNFT EIASKFSERL

651 QDFDKSNPIV LRMMNDQLMF LERAFIDPLG LPDRPFYRHV IYAPSSHNKY
701 AGESFPGIYD ALFDIESKVD PSKAWGEVKR QIYVAAFTVQ AAAETLSEVA

L5 ANSWER 22 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:77772 CAPLUS

DOCUMENT NUMBER: 124:139522

TITLE: Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase

AUTHOR(S): Carter, ruth E.; Feldman, Alexis R.; Coyle, Joseph T.

CORPORATE SOURCE: Dep. Psychiatry, Massachusetts General Hosp.-East, Charlestown, MA, 02129, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1996), 93(2), 749-53

CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This report demonstrates that the investigational prostatic carcinoma marker known as the prostate-specific membrane antigen (PSM) possesses hydrolytic activity with the substrate and pharmacol. properties of the N-acetylated α -linked acidic dipeptidase (NAALADase). NAALADase is a membrane hydrolase that has been characterized in the mammalian nervous system on the basis of its catabolism of the neuropeptide N-acetylasparylglutamate (NAAG) to yield glutamate and N-acetylaspertate and that has been hypothesized to influence glutamatergic signaling processes. The immunoscreening of a rat brain cDNA expression library with anti-NAALADase antisera identified a 1428-base partial cDNA that shares 86% sequence identity with 1428 bases of the human PSM cDNA [Israeli, R. S., Powell, C. T., Fair, W. R. & Heston, W. D. W. (1993) Cancer Res. 53, 227-230]. A cDNA containing the entire PSM open reading frame was subsequently isolated by reverse transcription-PCR from the PSM-pos. prostate carcinoma cell line LNCaP. Transient transfection of this cDNA into two NAALADase-neg. cell lines conferred NAAG-hydrolyzing activity that was inhibited by the NAALADase inhibitors quisqualic acid and β -NAAG. Thus we demonstrate a PSM-encoded function and identify a NAALADase-encoding cDNA. Northern analyses identify at least six transcripts that are variably expressed in NAALADase-pos. but not in NAALADase-neg. rat tissues and human cell lines; therefore, PSM and/or related mol. species appear to account for NAAG hydrolysis in the nervous system. These results also raise questions about the role of PSM in both normal and pathol. prostate epithelial-cell function.

IT 149200-79-3, Glycoprotein PSM (human clone 55A prostate-specific reduced)

RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)

(prostate-specific membrane antigen is a hydrolase possessing substrate and pharmacol. characteristics of a neuropeptidase)

RN 149200-79-3 CAPLUS

CN Glycoprotein PSM (human clone 55A prostate-specific reduced) (9CI) (CA INDEX NAME)

SEQ 1 MWNLLHETDS AVATARRPRW LCAGALVLAG GFFLLGFLFG WFIKSSNEAT
51 NITPKHNMKA FLDELKAENI KKFLYNFTQI PHLAGTEQNF QLAKQIQSQW
101 KEFGLDSVEL AHYDVLLSYP NKTHPNYISI INEDGNEIFN TSLFEPPPPG
151 YENVSDIVPP FSAFSPQGMP EGDLVYVNYA RTEDEFFKLER DMKINCSGKI
201 VIARYGKVFR GNKVKNAQLA GAKGVILYSD PADYFAPGVK SYPDGWNLP
251 GGVQRGNILN LNGAGDPLTP GYPANEYAYR RGIAEAVGLP SIPVHPIGYY

301 DAQKLLLEKMG GSAPPDSSWR GSLKVPYNVG PGFTGNFSTQ KVKMHIHSTN
 351 EVTRIYNVIG TLRGAVEPDR YVILGGHRDS WVFGGIDPQS GAAVVHEIVR
 401 SFGTLKKEGW RPRRTILFAS WDAEEFGLLG STEWAEENSR LLQERGVAYI
 451 NADSSIEGNY TLRVDCTPLM YSLVHNLTKE LKSPDEGFEG KSLYESWTKK
 501 SPSPEFSGMP RISKLGSGND FEVFFQRLGI ASGRARYTKN WETNKFSGYP
 551 LYHSVYETYE LVEKFYDPMF KYHLTVAQVR GGMVFELANS IVLPFDCRDY
 601 AVVLRKYADK IYSISMKHPQ EMKTYSVSFD SLFSAVKNFT EIASKFSERL
 651 QDFDKSNPIV LRMMNDQLMF LERAFIDPLG LPDRPFYRHV IYAPSSHNKY
 701 AGESFPGIYD ALFDIESKVD PSKAWGEVVR QIYVAAFTVQ AAAETLSEVA

L5 ANSWER 24 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:554861 CAPLUS

DOCUMENT NUMBER: 121:154861

TITLE: Prostate-specific membrane antigen

INVENTOR(S): Israeli, Ron S.; Heston, Warren D. W.; Fair, William R.

PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA

SOURCE: PCT Int. Appl., 191 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9409820	A1	19940511	WO 1993-US10624	19931105 <--
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2147499	A1	19940511	CA 1993-2147499	19931105 <--
EP 668777	A1	19950830	EP 1994-900538	19931105 <--
EP 668777	B1	20061011		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08506005	T	19960702	JP 1993-511426	19931105 <--
AT 342356	T	20061115	AT 1994-900538	19931105
US 5538866	A	19960723	US 1994-325553	19941018 <--
US 6953668	B1	20051011	US 1995-466381	19950602
US 7105159	B1	20060912	US 1995-470735	19950602
US 7070782	B1	20060704	US 1995-481916	19950607
US 2004198657	A1	20041007	US 2003-614625	20030702
US 2006177450	A1	20060810	US 2005-202940	20050811
PRIORITY APPLN. INFO.:			US 1992-973337	A 19921105
			WO 1993-US10624	W 19931105
			US 1994-325553	A1 19941018
			US 1995-394152	A1 19950224
			US 1995-403803	A1 19950317
			US 1995-466381	A2 19950602
			US 1995-470735	A2 19950602
			WO 1996-US2424	A2 19960223
			US 1996-705477	A1 19960829

AB The gene encoding a mammalian prostate-specific membrane antigen is cloned and expressed for characterization of the antigen and in the preparation of diagnostic and therapeutic agents. Hematogenous micrometastatic tumor cells can be detected by polymerase chain reaction (PCR) on samples of the subject using primers derived from the antigen gene. Methods to identify ligands of the antigen are described. The antigen was purified immunochem. from cells of lymph node carcinoma of prostate and amino acid sequence-derived primers were used to amplify the RNA from the same cells by degenerate PCR. The amplification product was then used to screen a cDNA bank to obtain a full-length cDNA.

IT 149200-79-3

RL: BIOL (Biological study)
(nucleotide sequence and cloning and expression of)

RN 149200-79-3 CAPLUS
CN Glycoprotein PSM (human clone 55A prostate-specific reduced) (9CI) (CA
INDEX NAME)

SEQ 1 MWNLLHETDS AVATARRPRW LCAGALVLAG GFFLLGFLFG WFIKSSNEAT
51 NITPKHNMKA FLDELKAENI KKFLYNFTQI PHLAGTEQNF QLAKQIQSQW
101 KEFGLDSVEL AHYDVLLSYP NKTHPNYISI INEDGNEIFN TSLFEPPPPG
151 YENVSDIVPP FSAFSPQGM EGDLYVNYA RTEDFFKLER DMKINCSGKI
201 VIARYGKVFR GNKVKNAQLA GAKGVILYSD PADYFAPGVK SYPDGNLPG
251 GGVQQRGNILN LNGAGDPLTP GYPANEYAYR RGIAEAVGLP SIPVHPIGYY
301 DAQKLLEKMG GSAPPDSSWR GSLKVPYNVG PGFTGNFSTQ KVKMHIHSTN
351 EVTRIYNVIG TLRGAVEPDR YVILGGHRDS WVFGGIDPQS GAAVVHEIVR
401 SFGTLKKEGW RPRRTILFAS WDAEEFGLLG STEWAEENSRLQERGVAYI
451 NADSSIEGNY TLRVDCTPLM YSLVHNLTKL LKSPDEGFEG KSLYESWTKK
501 SPSPEFSGMP RISKLGSGND FEVFFQRLGI ASGRARYTKN WETNKFSGYP
551 LYHSVYETYE LVEKFYDPMF KYHLTVQVR GGMVFELANS IVLPFDCRDY
601 AVVLRKYADK IYSISMKHPQ EMKTYSVSFD SLFSAVKNFT EIASKFSERL
651 QDFDKSNPIV LRMMNDQLMF LERAFIDPLG LPDRPFYRHV IYAPSSHNY
701 AGESFPGIYD ALFDIESKVD PSKAWGEVKR QIYVAFTVQ AAAETLSEVA

L5 ANSWER 25 OF 25 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:493193 CAPLUS

DOCUMENT NUMBER: 119:93193

TITLE: Molecular cloning of a complementary DNA encoding a
prostate-specific membrane antigen

AUTHOR(S): Israeli, Ron S.; Powell, C. Thomas; Fair, William R.;
Heston, Warren D. W.

CORPORATE SOURCE: Urol. Oncol. Res. Lab., Memor. Sloan-Kettering Cancer
Cent., New York, NY, 10021, USA

SOURCE: Cancer Research (1993), 53(2), 227-30

CODEN: CNREA8; ISSN: 0008-5472

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Recently, a novel Mr 100,000 prostate-specific membrane glycoprotein (PSM) was detected by the prostate-specific monoclonal antibody 7E11-C5, raised against the human prostatic carcinoma cell line LNCaP. The PSM antigen is expressed exclusively by normal and neoplastic prostate cells and metastases. A full-length 2.65-kilobase cDNA encoding the PSM antigen was cloned from a human LNCaP cDNA library by polymerase chain reaction using degenerate oligonucleotide primers. Anal. of the cDNA sequence has revealed that a portion of the coding region, from nucleotide 1250 to 1700, has 54% homol. to the human transferrin receptor mRNA. The deduced polypeptide has a putative transmembrane domain enabling the delineation of intra- and extracellular portions of this antigen. In contrast to prostate-specific antigen and prostatic acid phosphatase which are secreted proteins, PSM as an integral membrane protein may prove to be effective as a target for imaging and cytotoxic targeting modalities.

IT 149200-79-3

RL: PRP (Properties)

(amino acid sequence of, complete)

RN 149200-79-3 CAPLUS

CN Glycoprotein PSM (human clone 55A prostate-specific reduced) (9CI) (CA
INDEX NAME)

SEQ 1 MWNLLHETDS AVATARRPRW LCAGALVLAG GFFLLGFLFG WFIKSSNEAT
51 NITPKHNMKA FLDELKAENI KKFLYNFTQI PHLAGTEQNF QLAKQIQSQW
101 KEFGLDSVEL AHYDVLLSYP NKTHPNYISI INEDGNEIFN TSLFEPPPPG

151 YENVSDIVPP FSAFSPQGMP EGDLYVYVNYA RTEDFFKLER DMKINCSGKI
201 VIARYGKVFR GNKVNAQLA GAKGVILYSD PADYFAPGVK SYPDGWNLPG
251 GGVQRGNILN LNGAGDPLTP GYPANEYAYR RGIAEAVGLP SIPVHPIGYY
301 DAQKLEKMG GSAPPDSSWR GSLKVPYNVG PGFTGNFSTQ KVKMHIHSTN
351 EVTRIYNVIG TLRGAVEPDR YVILGGHRDS WVFGGIDPQS GAÄVVHEIVR
401 SFGTLKKEGW RPRRTILFAS WDAEEFGLLG STEWAEENSRLQERGVAYI
451 NADSSIEGNY TLRVDCTPLM YSLVHNLTKE LKSPDEGFEG KSLYESWTKK
501 SPSPEFSGMP RISKLGSGND FEVFFQRLGI ASGRARYTKN WETNKFSGYP
551 LYHSVYETYE LVEKFYDPMF KYHLTVAQVR GGMVFELANS IVLPFD CRDY
601 AVVLRKYADK IYSISMKHPQ EMKTYSVSFD SLFSAVKNFT EIASKFSERL
651 QDFDKSNPIV LRMMNDQLMF LERAFIDPLG LPDRPFYRHV IYAPSSHNKY
701 AGESFPGIYD ALFDIESKVD PSKAWGEVKR QIYVAAFTVQ AAAETLSEVA